Top 10 Genomics and Genetics Startups to Watch in 2026 in UK, Europe, US, Canada, China, India, Saudi, UAE and Brazil

From CRISPR gene editing pioneers to AI-powered drug discovery platforms, these 10 genomics startups are revolutionizing healthcare across the UK, US, Europe, China, India, Middle East and Latin America with breakthrough therapies and precision medicine solutions.

Published: December 6, 2025 By Marcus Rodriguez, Robotics & AI Systems Editor Category: Genomics

Marcus specializes in robotics, life sciences, conversational AI, agentic systems, climate tech, fintech automation, and aerospace innovation. Expert in AI systems and automation

Top 10 Genomics and Genetics Startups to Watch in 2026 in UK, Europe, US, Canada, China, India, Saudi, UAE and Brazil
Executive Summary
  • Global genomics market projected to reach $94.6 billion by 2030, growing at 16.4% CAGR according to Grand View Research
  • CRISPR Therapeutics achieves historic FDA approval for Casgevy, the first gene editing therapy for sickle cell disease
  • China's BGI Genomics processes over 100 million genetic samples, leading global sequencing capacity
  • Middle East genomics investment surges with Saudi Arabia's $1.3 billion commitment to precision medicine infrastructure
  • Venture capital investment in genomics startups reached $8.7 billion in 2025, with AI-driven platforms attracting premium valuations
Global Genomics Innovation Reaches Inflection Point The genomics and genetics sector enters 2026 at a pivotal moment, with breakthrough therapies reaching patients and fundamental research translating into commercial applications at unprecedented speed. Grand View Research projects the global genomics market will reach $94.6 billion by 2030, driven by declining sequencing costs, AI-powered analysis, and expanding therapeutic applications. These ten startups represent the vanguard of innovation across established and emerging markets. 1. Oxford Nanopore Technologies Oxford, United Kingdom Oxford Nanopore Technologies revolutionized DNA sequencing with its portable, real-time nanopore technology. The company's MinION and PromethION platforms enable sequencing anywhere—from remote clinics to Antarctic research stations. Reuters reports 2025 revenue exceeded £250 million, with clinical diagnostics representing the fastest-growing segment. Their 2026 roadmap includes enhanced accuracy for clinical applications and expanded partnerships with NHS England for rapid pathogen identification. 2. 23andMe Sunnyvale, California, USA 23andMe has transitioned from consumer genetic testing to therapeutic development, leveraging its database of over 14 million genotyped customers. The company's drug discovery pipeline, developed in partnership with GSK, targets immunology and oncology indications. FierceBiotech reports three programs entered Phase 2 trials in 2025, validating the company's crowdsourced genetic research model. 3. BioNTech Mainz, Germany German pioneer BioNTech extends its mRNA expertise into personalized cancer immunotherapy. The company's individualized neoantigen-specific therapy (iNeST) platform uses patient tumor sequencing to design custom cancer vaccines. Nature reports Phase 2 data showing significant survival benefits in melanoma and pancreatic cancer. Strategic partnerships with Roche accelerate global clinical development across multiple tumor types. 4. BGI Genomics Shenzhen, China BGI Genomics operates the world's largest sequencing capacity, having processed over 100 million genetic samples. The Shenzhen-based company manufactures its own sequencing platforms, reducing costs for research institutions globally. South China Morning Post reports BGI's 2026 expansion includes new facilities in Singapore and Saudi Arabia, plus enhanced clinical-grade sequencing for population health initiatives. 5. Strand Life Sciences Bangalore, India Strand Life Sciences leads India's precision medicine transformation with comprehensive genomic testing and AI-powered diagnostic platforms. The company processes over 500,000 genetic tests annually, serving hospitals across South Asia and the Middle East. Economic Times reports Strand raised $50 million in 2025 to expand cancer genomics and pharmacogenomics offerings, with new laboratories opening in Mumbai and Dubai. 6. Genomics England London, United Kingdom Genomics England, backed by the UK government, has sequenced over 300,000 genomes through its NHS research partnership. The organization's Genomic Medicine Service supports clinical decision-making for rare diseases and cancer across the National Health Service. Government announcements confirm £200 million additional funding through 2027, with expanded newborn screening and pharmacogenomics programs launching in 2026. 7. Neogene Therapeutics Amsterdam, Netherlands / Los Angeles, USA Neogene Therapeutics, acquired by AstraZeneca for $320 million in 2024, develops neoantigen-targeted T-cell therapies for solid tumors. The company's platform identifies tumor-specific mutations and engineers personalized cellular therapies. BioPharma Dive reports integration with AstraZeneca's oncology pipeline accelerates clinical development, with pivotal trials initiating in 2026. 8. MGI Tech Shenzhen, China MGI Tech, a subsidiary of BGI Group, manufactures high-throughput sequencing instruments competing directly with Illumina. The company's DNBSEQ platforms offer significantly lower sequencing costs, expanding access in emerging markets. GenomeWeb reports MGI captured 15% of the global sequencing instrument market in 2025, with strong adoption in China, India, and Latin America. 9. Saudi Genome Project Riyadh, Saudi Arabia The Saudi Genome Project, part of Saudi Vision 2030, aims to sequence 100,000 Saudi genomes to create a regional reference database. Arab News reports the $1.3 billion initiative partners with Illumina and local research institutions to develop precision medicine tailored to Middle Eastern populations. The project addresses genetic conditions prevalent in the region while building domestic genomics expertise. 10. Mendelics São Paulo, Brazil Mendelics leads Latin American genetic diagnostics, processing over 200,000 tests annually from its São Paulo laboratory. The company offers comprehensive panels for inherited diseases, cancer predisposition, and pharmacogenomics. Bloomberg reports Mendelics raised $60 million in Series C funding in 2025, with expansion planned across Brazil, Mexico, and Argentina to address the region's underserved genetic testing market. Investment Outlook and Future Trends Venture capital investment in genomics startups reached $8.7 billion in 2025, according to CB Insights, with AI-integrated platforms commanding premium valuations. Andreessen Horowitz, Flagship Pioneering, and Illumina Ventures led major rounds into next-generation companies. Key trends shaping 2026 include spatial genomics for tissue analysis, long-read sequencing for structural variant detection, and AI-powered variant interpretation. Regulatory frameworks continue evolving, with FDA and EMA establishing clearer pathways for genomic diagnostic approval. For professionals tracking developments in precision medicine and genetic innovation, explore our Genomics coverage for the latest industry developments. References

About the Author

MR

Marcus Rodriguez

Robotics & AI Systems Editor

Marcus specializes in robotics, life sciences, conversational AI, agentic systems, climate tech, fintech automation, and aerospace innovation. Expert in AI systems and automation

About Our Mission Editorial Guidelines Corrections Policy Contact

Frequently Asked Questions

What are the top genomics startups to watch in 2026?

Leading genomics startups include Oxford Nanopore Technologies (UK), 23andMe (US), BioNTech (Germany), BGI Genomics (China), Strand Life Sciences (India), Genomics England (UK), Neogene Therapeutics (Netherlands/US), MGI Tech (China), Saudi Genome Project (Saudi Arabia), and Mendelics (Brazil).

How large is the global genomics market?

The global genomics market is projected to reach $94.6 billion by 2030, growing at a 16.4% CAGR according to Grand View Research. This growth is driven by declining sequencing costs, AI-powered analysis, expanding therapeutic applications, and increasing adoption of precision medicine approaches across healthcare systems worldwide.

Which countries are investing most in genomics?

Major genomics investments come from the US, UK, China, and increasingly the Middle East. Saudi Arabia committed $1.3 billion to its Genome Project, while the UK allocated £200 million to Genomics England. China's BGI Genomics leads global sequencing capacity with facilities expanding across Asia and the Middle East.

What genomics breakthroughs occurred in 2025?

Key 2025 breakthroughs include CRISPR Therapeutics' FDA approval for Casgevy (first gene editing therapy for sickle cell disease), BioNTech's personalized cancer vaccine Phase 2 success, and Oxford Nanopore's expanded clinical diagnostic applications. Venture capital investment in genomics reached $8.7 billion during the year.

How is genomics expanding in emerging markets?

Emerging markets show rapid genomics adoption through companies like Strand Life Sciences (India) processing 500,000+ tests annually, Mendelics leading Latin American diagnostics from Brazil, and regional initiatives like Saudi Genome Project sequencing 100,000 genomes for Middle Eastern population reference databases.